Testosterone vs Masteron: What to Choose and for Whom

In athletic communities masteron is often described as an "aesthetic" steroid, and testosterone as a "base." Such logic sidesteps the main question: for whom there is any justified use of these substances at all. The editorial team examines the choice between testosterone and drostanolone through the lens of medical indications and individual risk factors.

Where the question of choice comes from

The popularity of comparing testosterone with masteron stems from the fact that these substances have opposite "reputations." Testosterone is associated with mass gain and water, masteron with a "dry" appearance and the absence of estrogenic effects. These notions partly have a pharmacological basis but are greatly oversimplified.

In informal sources the choice is usually framed through the desired outward result. However, for health other questions matter: is there a medical condition requiring treatment; what individual risks does the person have; do they undergo doping control; do they plan to have children.

The editorial team proposes considering the choice precisely through these questions. Such an approach does not provide a "prescription," but it allows one to understand why for most people the correct answer is not to use either substance without medical indications.

It is also important to remember that information about masteron's effects in athletic circles comes mainly from users' personal experience rather than from controlled studies. Such testimony is prone to bias and does not account for long-term consequences.

The medical scenario: testosterone only

The only situation in which modern medicine considers androgen therapy in men is confirmed hypogonadism with clinical symptoms. In that case, current guidelines call for testosterone products: injectable esters, gels, and, in some countries, oral undecanoate.

The reason is simple: testosterone reproduces the natural hormone and provides all of its effects, including those realized through estradiol. For a man's bones, libido, and metabolism this matters. A non-aromatizing androgen does not perform this function.

During testosterone therapy the physician monitors a number of indicators. The list is based on the Endocrine Society guideline:

1. testosterone level a defined time after the start of treatment;
2. hematocrit — at baseline and over time;
3. PSA and prostate condition in men of the appropriate age;
4. bone mineral density in osteoporosis;
5. assessment of symptoms and side effects at each visit.

Masteron does not figure in such a scheme at all. Even if a patient is predisposed to gynecomastia, the physician adjusts the form or regimen of testosterone rather than replacing it with a DHT derivative.

Why masteron disappeared from medicine

Drostanolone propionate was used in the second half of the twentieth century for the palliative treatment of advanced breast cancer in postmenopausal women. Androgens in general were one of the options for hormonal therapy of this disease before the appearance of modern drugs.

Over time, tamoxifen and then aromatase inhibitors demonstrated better efficacy and significantly less virilizing action. Androgen therapy for breast cancer lost its significance, and drostanolone products gradually disappeared from pharmaceutical markets.

Drostanolone had no other official indications related to men. Therefore, today there is no medical situation in which a physician would choose masteron instead of testosterone.

The practical significance of this fact for the reader is as follows: any "masteron" available today is almost certainly manufactured outside pharmaceutical control. Analyses of illegal steroid products have repeatedly revealed a discrepancy with the declared composition.

Individual factors that change the risks

Even under identical conditions two people can have different risks from the same substances. Below are the factors that the editorial team considers most important in assessing dangers, rather than in "choosing a drug."

As the table shows, the "advantages" of masteron on some points are offset by disadvantages on others. There is no profile of a person for whom drostanolone would be unambiguously safer than testosterone.

Cardiovascular risks are worth mentioning separately. Studies of anabolic steroid users show a reduced left ventricular ejection fraction and a greater volume of coronary plaque compared with non-users. These data apply to the class of substances as a whole and give no grounds for singling out any steroid as "cardio-safe."

Mental state also matters: androgens can heighten irritability, and after discontinuation symptoms resembling depression often develop due to suppression of one's own hormonal axis.

Women and masteron: debunking the myth

In informal sources masteron is sometimes called a "mild steroid for women." The argument is the historical use of drostanolone in women with breast cancer. However, in oncology virilization was accepted as an unavoidable price for treating a serious illness, not as an absent risk.

Drostanolone is a full-fledged androgen, a DHT derivative. In women it can cause deepening of the voice, growth of facial and body hair, clitoral enlargement, menstrual cycle disturbances, and acne. Changes to the voice and clitoris are often irreversible.

Medicine uses testosterone in women extremely sparingly: a 2019 international consensus statement recognizes the only evidence-based indication as hypoactive sexual desire disorder in postmenopausal women, and only at doses that reproduce physiological female concentrations.

Thus, for a woman outside this narrow medical scenario neither substance is acceptable. The "choice" between them is a choice between two kinds of virilization risk.

For female athletes undergoing testing, the anti-doping aspect additionally applies: both testosterone and drostanolone are included in section S1 of the WADA Prohibited List.

Editorial conclusions

In a medical context there is no choice between testosterone and masteron: for confirmed hypogonadism, testosterone products are used under a physician's supervision.

Masteron lost its medical significance back in the last century, and modern products bearing this name come predominantly from the illegal market.

Individual factors — predisposition to baldness, lipid status, plans regarding children — change the risk profile, but do not make either substance safe for non-medical use. For women both substances carry a risk of irreversible virilization.

We also recommend reading our materials on the diagnosis of hypogonadism, on the effects of androgens on the heart, and on how the hormonal system recovers after their use.

References

1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.
2. Davis SR, Baber R, Panay N, et al. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660–4666.
3. Baggish AL, Weiner RB, Kanayama G, et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation. 2017;135(21):1991–2002.
4. Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
5. Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502–521.
6. Kanayama G, Hudson JI, Pope HG Jr. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern? Drug Alcohol Depend. 2008;98(1–2):1–12.
7. World Anti-Doping Agency. The Prohibited List. International Standard. Montreal: WADA; 2025.